Search

Your search keyword '"Specht, Jennifer M."' showing total 206 results
Start Over Author "Specht, Jennifer M."
206 results on '"Specht, Jennifer M."'

4. Digital Mammography and Breast Tomosynthesis Performance in Women with a Personal History of Breast Cancer, 2007-2016.

Author

Lee, Janie M, Ichikawa, Laura E, Wernli, Karen J, Bowles, Erin, Specht, Jennifer M, Kerlikowske, Karla, Miglioretti, Diana L, Lowry, Kathryn P, Tosteson, Anna NA, Stout, Natasha K, Houssami, Nehmat, Onega, Tracy, and Buist, Diana SM

Subjects
Humans, Breast Neoplasms, Neoplasm Recurrence, Local, Mammography, Mass Screening, Population Surveillance, Registries, Sensitivity and Specificity, Prospective Studies, Predictive Value of Tests, Adult, Aged, Middle Aged, United States, Female, Breast Cancer, Prevention, Biomedical Imaging, Clinical Research, Cancer, Medical and Health Sciences, Nuclear Medicine & Medical Imaging
Abstract

Background Since 2007, digital mammography and digital breast tomosynthesis (DBT) replaced screen-film mammography. Whether these technologic advances have improved diagnostic performance has, to the knowledge of the authors, not yet been established. Purpose To evaluate the performance and outcomes of surveillance mammography (digital mammography and DBT) performed from 2007 to 2016 in women with a personal history of breast cancer and compare with data from 1996 to 2007 and the performance of digital mammography screening benchmarks. Materials and Methods In this observational cohort study, five Breast Cancer Surveillance Consortium registries provided prospectively collected mammography data linked with tumor registry and pathologic outcomes. This study identified asymptomatic women with American Joint Committee on Cancer anatomic stages 0-III primary breast cancer who underwent surveillance mammography from 2007 to 2016. The primary outcome was a second breast cancer diagnosis within 1 year of mammography. Performance measures included the recall rate, cancer detection rate, interval cancer rate, positive predictive value of biopsy recommendation, sensitivity, and specificity. Results Among 32 331 women who underwent 117 971 surveillance mammographic examinations (112 269 digital mammographic examinations and 5702 DBT examinations), the mean age at initial diagnosis was 59 years ± 12 (standard deviation). Of 1418 second breast cancers diagnosed, 998 were surveillance-detected cancers and 420 were interval cancers. The recall rate was 8.8% (10 365 of 117 971; 95% CI: 8.6%, 9.0%), the cancer detection rate was 8.5 per 1000 examinations (998 of 117 971; 95% CI: 8.0, 9.0), the interval cancer rate was 3.6 per 1000 examinations (420 of 117 971; 95% CI: 3.2, 3.9), the positive predictive value of biopsy recommendation was 31.0% (998 of 3220; 95% CI: 29.4%, 32.7%), the sensitivity was 70.4% (998 of 1418; 95% CI: 67.9%, 72.7%), and the specificity was 98.1% (114 331 of 116 553; 95% CI: 98.0%, 98.2%). Compared with previously published studies, interval cancer rate was comparable with rates from 1996 to 2007 in women with a personal history of breast cancer and was higher than the published digital mammography screening benchmarks. Conclusion In transitioning from screen-film to digital mammography and digital breast tomosynthesis, surveillance mammography performance demonstrated minimal improvement over time and remained inferior to the performance of screening mammography benchmarks. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Moy and Gao in this issue.

Published
2021

6. qPCR assay for detection of Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Elements from CAR-T and TCR-T cells in fresh and formalin-fixed tissue

Author

Pullarkat, Shalini, primary, Black, Graeme, additional, Bleakley, Marie, additional, Buenrostro, Denise, additional, Chapuis, Aude G., additional, Hirayama, Alexandre V., additional, Jaeger-Ruckstuhl, Carla A., additional, Kimble, Erik L., additional, Lee, Bo M., additional, Maloney, David G., additional, Radich, Jerald, additional, Seaton, Brandon W., additional, Specht, Jennifer M., additional, Turtle, Cameron J., additional, Woolston, David W., additional, Wright, Jocelyn H., additional, and Yeung, Cecilia C. S., additional

Published
2024
Full Text
View/download PDF

7. RNA-Seq based gene expression profiling of baseline and on-treatment breast tumors to predict response to HER2-directed therapy, without chemotherapy (TBCRC026).

Author

Hennessy, Maeve, primary, Fernández, Aranzazu, additional, Huang, Chiung Yu, additional, Cimino-Mathews, Ashley, additional, Denbow, Rita, additional, Abramson, Vandana G, additional, Rimawi, Mothaffar F., additional, Specht, Jennifer M., additional, Storniolo, Anna Maria, additional, Valero, Vicente, additional, Vaklavas, Chris, additional, Winer, Eric P., additional, Krop, Ian E., additional, Wolff, Antonio C., additional, Wahl, Richard L., additional, Thompson, E Aubrey, additional, Stearns, Vered, additional, Perou, Charles, additional, Carey, Lisa A., additional, and Connolly, Roisin M., additional

Published
2024
Full Text
View/download PDF

8. Improving ethnic and racial diversity in biomarker-driven clinical trials: A proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH).

Author

Smith, Caleb Joshua, primary, Simeone, Diane M., additional, Grierson, Patrick, additional, Kirtane, Kedar, additional, Morelli, Maria Pia, additional, Patel, Sandip Pravin, additional, Ulrickson, Matthew L., additional, Dahiya, Saurabh, additional, Park, Jong Chul, additional, Specht, Jennifer M., additional, Fakih, Marwan, additional, Liechty, Kirstin B., additional, Tebbets, Jessica, additional, Welch, John Sutton, additional, Go, William Y., additional, Maloney, David G., additional, Maus, Marcela Valderrama, additional, Ng, Eric Wai-Choi, additional, and Hecht, J. Randolph, additional

Published
2024
Full Text
View/download PDF

9. Correlation of TILs indices generated by visual review and digital computational algorithm with outcomes from preoperative chemotherapy for TNBC in TBCRC 030.

Author

Nader Marta, Guilherme, primary, Chu, Xiangying, additional, Mukhopadhyay, Satabhisa, additional, Abramson, Vandana G, additional, Brufsky, Adam, additional, Stringer-Reasor, Erica Michelle, additional, Dent, Susan Faye, additional, Traina, Tiffany A., additional, Carey, Lisa A., additional, Rimawi, Mothaffar F., additional, Specht, Jennifer M., additional, Miller, Kathy, additional, Santa-Maria, Cesar Augusto, additional, Dasgupta, Tathagata, additional, Binboğa Kurt, Busem, additional, Tayob, Nabihah, additional, Krop, Ian E., additional, Tung, Nadine M., additional, Schnitt, Stuart J., additional, and Mayer, Erica L., additional

Published
2024
Full Text
View/download PDF

10. A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer

Author

Symonds, Lynn, Jenkins, Isaac, Linden, Hannah M, Kurland, Brenda, Gralow, Julie R, Gadi, Vijayakrishna (V.K.), Ellis, Georgiana K, Wu, Qian, Rodler, Eve, Chalasani, Pavani, Chai, Xiaoyu, Riedel, Jinny, SCCA Network Investigators, Stopeck, Alison, Brown-Glaberman, Ursa, and Specht, Jennifer M

Published
2022
Full Text
View/download PDF

11. ACR Appropriateness Criteria® Imaging of Invasive Breast Cancer.

Author

McDonald, Elizabeth S., Scheel, John R., Lewin, Alana A., Weinstein, Susan P., Dodelzon, Katerina, Dogan, Basak E., Fitzpatrick, Amy, Kuzmiak, Cherie M., Newell, Mary S., Paulis, Lisa V., Pilewskie, Melissa, Salkowski, Lonie R., Silva, H. Colleen, Sharpe, Richard E., Specht, Jennifer M., Ulaner, Gary A., and Slanetz, Priscilla J.

Abstract

As the proportion of women diagnosed with invasive breast cancer increases, the role of imaging for staging and surveillance purposes should be determined based on evidence-based guidelines. It is important to understand the indications for extent of disease evaluation and staging, as unnecessary imaging can delay care and even result in adverse outcomes. In asymptomatic patients that received treatment for curative intent, there is no role for imaging to screen for distant recurrence. Routine surveillance with an annual 2-D mammogram and/or tomosynthesis is recommended to detect an in-breast recurrence or a new primary breast cancer in women with a history of breast cancer, and MRI is increasingly used as an additional screening tool in this population, especially in women with dense breasts. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Repeatability of 18F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trials

Author

Muzi, Mark, primary, Peterson, Lanell M., additional, Specht, Jennifer M., additional, Hippe, Daniel S., additional, Novakova-Jiresova, Alena, additional, Lee, Jean H., additional, Kurland, Brenda F., additional, Mankoff, David A., additional, Obuchowski, Nancy, additional, Linden, Hannah M., additional, and Kinahan, Paul E., additional

Published
2024
Full Text
View/download PDF

13. Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer

Author

Rodler, Eve T, Kurland, Brenda F, Griffin, Melissa, Gralow, Julie R, Porter, Peggy, Yeh, Rosa F, Gadi, Vijayakrishna K, Guenthoer, Jamie, Beumer, Jan H, Korde, Larissa, Strychor, Sandra, Kiesel, Brian F, Linden, Hannah M, Thompson, John A, Swisher, Elizabeth, Chai, Xiaoyu, Shepherd, Stacie, Giranda, Vincent, and Specht, Jennifer M

Subjects
Clinical Research, Cancer, Breast Cancer, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Antineoplastic Agents, Phytogenic, Antineoplastic Combined Chemotherapy Protocols, BRCA2 Protein, Benzimidazoles, Cisplatin, DNA Repair, Disease-Free Survival, Female, Humans, Middle Aged, Poly Adenosine Diphosphate Ribose, Poly(ADP-ribose) Polymerase Inhibitors, Receptor, ErbB-2, Receptors, Estrogen, Receptors, Progesterone, Triple Negative Breast Neoplasms, Ubiquitin-Protein Ligases, Vinblastine, Vinorelbine, Receptor, erbB-2, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeCisplatin is synergistic with vinorelbine and the PARP inhibitor veliparib, and has antineoplastic activity in triple-negative breast cancer (TNBC) and BRCA mutation-associated breast cancer. This phase I study assessed veliparib with cisplatin and vinorelbine.Experimental designA 3+3 dose-escalation design evaluated veliparib administered twice daily for 14 days with cisplatin (75 mg/m(2) day 1) and vinorelbine (25 mg/m(2) days 1, 8) every 21 days, for 6 to 10 cycles, followed by veliparib monotherapy. Pharmacokinetics, measurement of poly(ADP-ribose) in peripheral blood mononuclear cells, and preliminary efficacy were assessed. IHC and gene-expression profiling were evaluated as potential predictors of response.ResultsForty-five patients enrolled in nine dose cohorts plus five in an expansion cohort at the highest dose level and recommended phase II dose, 300 mg twice daily. The MTD of veliparib was not reached. Neutropenia (36%), anemia (30%), and thrombocytopenia (12%) were the most common grade 3/4 adverse events. Best overall response for 48 patients was radiologic response with 9-week confirmation for 17 (35%; 2 complete, 15 partial), and stable disease for 21 (44%). Germline BRCA mutation presence versus absence was associated with 6-month progression-free survival [PFS; 10 of 14 (71%) vs. 8 of 27 (30%), mid-P = 0.01]. Median PFS for all 50 patients was 5.5 months (95% confidence interval, 4.1-6.7).ConclusionsVeliparib at 300 mg twice daily combined with cisplatin and vinorelbine is well tolerated with encouraging response rates. A phase II randomized trial is planned to assess veliparib's contribution to cisplatin chemotherapy in metastatic TNBC and BRCA mutation-associated breast cancer. Clin Cancer Res; 22(12); 2855-64. ©2016 AACR.

Published
2016

15. Repeatability of 18F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trials.

Author

Muzi, Mark, Peterson, Lanell M., Specht, Jennifer M., Hippe, Daniel S., Novakova-Jiresova, Alena, Lee, Jean H., Kurland, Brenda F., Mankoff, David A., Obuchowski, Nancy, Linden, Hannah M., and Kinahan, Paul E.

Subjects
CANCER patients, STERNUM, BREAST cancer, CLINICAL trials, PROGRESSION-free survival, CONFIDENCE intervals, MAGNETIC resonance mammography, STATISTICAL reliability
Abstract

Background: Standard measures of response such as Response Evaluation Criteria in Solid Tumors are ineffective for bone lesions, often making breast cancer patients that have bone-dominant metastases ineligible for clinical trials with potentially helpful therapies. In this study we prospectively evaluated the test-retest uptake variability of 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG) in a cohort of breast cancer patients with bone-dominant metastases to determine response criteria. The thresholds for 95% specificity of change versus no-change were then applied to a second cohort of breast cancer patients with bone-dominant metastases. Methods: For this study, nine patients with 38 bone lesions were imaged with 18F-FDG in the same calibrated scanner twice within 14 days. Tumor uptake was quantified by the most commonly used PET parameter, the maximum tumor voxel normalized by dose and body weight (SUVmax) and also by the mean of a 1-cc maximal uptake volume normalized by dose and lean-body-mass (SULpeak). The asymmetric repeatability coefficients with confidence intervals for SUVmax and SULpeak were used to determine the limits of 18F-FDG uptake variability. A second cohort of 28 breast cancer patients with bone-dominant metastases that had 146 metastatic bone lesions was imaged with 18F-FDG before and after standard-of-care therapy for response assessment. Results: The mean relative difference of SUVmax and SULpeak in 38 bone tumors of the first cohort were 4.3% and 6.7%. The upper and lower asymmetric limits of the repeatability coefficient were 19.4% and − 16.3% for SUVmax, and 21.2% and − 17.5% for SULpeak. 18F-FDG repeatability coefficient confidence intervals resulted in the following patient stratification using SULpeak for the second patient cohort: 11-progressive disease, 5-stable disease, 7-partial response, and 1-complete response with three inevaluable patients. The asymmetric repeatability coefficients response criteria for SULpeak changed the status of 3 patients compared to the standard Positron Emission Tomography Response Criteria in Solid Tumors of ± 30% SULpeak. Conclusion: In evaluating bone tumor response for breast cancer patients with bone-dominant metastases using 18F-FDG SUVmax, the repeatability coefficients from test-retest studies show that reductions of more than 17% and increases of more than 20% are unlikely to be due to measurement variability. Serial 18F-FDG imaging in clinical trials investigating bone lesions in these patients, such as the ECOG-ACRIN EA1183 trial, benefit from confidence limits that allow interpretation of response. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Data from Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer

Author

Linden, Hannah M., primary, Kurland, Brenda F., primary, Peterson, Lanell M., primary, Schubert, Erin K., primary, Gralow, Julie R., primary, Specht, Jennifer M., primary, Ellis, Georgiana K., primary, Lawton, Thomas J., primary, Livingston, Robert B., primary, Petra, Philip H., primary, Link, Jeanne M., primary, Krohn, Kenneth A., primary, and Mankoff, David A., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Legend from Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer

Author

Linden, Hannah M., primary, Kurland, Brenda F., primary, Peterson, Lanell M., primary, Schubert, Erin K., primary, Gralow, Julie R., primary, Specht, Jennifer M., primary, Ellis, Georgiana K., primary, Lawton, Thomas J., primary, Livingston, Robert B., primary, Petra, Philip H., primary, Link, Jeanne M., primary, Krohn, Kenneth A., primary, and Mankoff, David A., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure 1A-B from Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer

Author

Linden, Hannah M., primary, Kurland, Brenda F., primary, Peterson, Lanell M., primary, Schubert, Erin K., primary, Gralow, Julie R., primary, Specht, Jennifer M., primary, Ellis, Georgiana K., primary, Lawton, Thomas J., primary, Livingston, Robert B., primary, Petra, Philip H., primary, Link, Jeanne M., primary, Krohn, Kenneth A., primary, and Mankoff, David A., primary

Published
2023
Full Text
View/download PDF

27. Abstract P3-01-05: Laboratory monitoring in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer treated with palbociclib in a real-world setting: Results from POLARIS

Author

Rocque, Gabrielle B., primary, Blum, Joanne L., additional, Specht, Jennifer M., additional, Dul, Carrie, additional, Corso, Steven, additional, Cuevas, Daniel, additional, Gauthier, Eric, additional, Montelongo, Monica Z., additional, Zhang, Zhe, additional, Wang, Yao, additional, and Tripathy, Debu, additional

Published
2023
Full Text
View/download PDF

29. Abstract PD11-06: PD11-06 Circulating tumor DNA association with residual cancer burden after neoadjuvant therapy in triple negative breast cancer in TBCRC 030

Author

Parsons, Heather A., primary, Blewett, Timothy, additional, Chu, Xiangying, additional, Sridhar, Sainetra, additional, Santos, Katheryn, additional, Xiong, Kan, additional, Abramson, Vandana, additional, Patel, Ashka, additional, Cheng, Ju, additional, Brufsky, Adam M., additional, Rhoades, Justin, additional, Force, Jeremy, additional, Liu, Ruolin, additional, Traina, Tiffany A., additional, Carey, Lisa, additional, Rimawi, Mothaffar, additional, Elkhanany, Ahmed, additional, Stearns, Vered, additional, Specht, Jennifer M., additional, Burstein, Harold, additional, Wolff, Antonio C., additional, Winer, Eric, additional, Tayob, Nabihah, additional, Krop, Ian, additional, Golub, Todd, additional, Mayer, Erica L., additional, and Adalsteinsson, Viktor, additional

Published
2023
Full Text
View/download PDF

30. Abstract P2-03-25: Pilot study to evaluate circulating tumor DNA (ctDNA) to PET/CT imaging using 18F-Fluorodeoxyglucose (FDG) and 18F-Fluoroestradiol (FES) PET/CT imaging as biomarkers in patients with metastatic breast cancer

Author

Hunter, Natasha, primary, Peterson, Lanell M., additional, Muzi, Mark, additional, Konnick, Eric Q., additional, Reichel, Jonathan, additional, Kinahan, Paul, additional, Specht, Jennifer M., additional, Yung, Rachel, additional, Gwin, William R., additional, Linden, Hannah, additional, and Tran, Christina, additional

Published
2023
Full Text
View/download PDF

31. Abstract PD13-05: PD13-05 Updated results of a Phase 1b study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: Subgroup analysis by PIK3CA mutation status

Author

Wesolowski, Robert, primary, Rugo, Hope, additional, Stringer-Reasor, Erica, additional, Han, Hyo S., additional, Specht, Jennifer M., additional, Dees, E. Claire, additional, Kabos, Peter, additional, Vaishampayan, Ulka, additional, Wander, Seth A., additional, Lu, Janice, additional, Gogineni, Keerthi, additional, Spira, Alexander I., additional, Schott, Anne F., additional, Abu-Khalaf, Maysa, additional, Nayak, Pratima, additional, Sullivan, Brian F., additional, Gorbatchevsky, Igor, additional, and Layman, AND Rachel M., additional

Published
2023
Full Text
View/download PDF

32. Variation in second breast cancer risk after primary invasive cancer by time since primary cancer diagnosis and estrogen receptor status

Author

Lowry, Kathryn P., primary, Ichikawa, Laura, additional, Hubbard, Rebecca A., additional, Buist, Diana S. M., additional, Bowles, Erin J. A., additional, Henderson, Louise M., additional, Kerlikowske, Karla, additional, Specht, Jennifer M., additional, Sprague, Brian L., additional, Wernli, Karen J., additional, and Lee, Janie M., additional

Published
2023
Full Text
View/download PDF

36. A phase 1 multiple-ascending dose study to evaluate the safety and tolerability of XmAb23104 (PD-1 x ICOS) in subjects with selected advanced solid tumors (DUET-3).

Author

Akce, Mehmet, primary, Hu-Lieskovan, Siwen, additional, Reilley, Matthew, additional, Strauss, James Fredric, additional, Specht, Jennifer M., additional, Stein, Mark N., additional, Wang, Judy S., additional, Choe, Jennifer Hsing, additional, Leidner, Rom, additional, Davar, Diwakar, additional, Falchook, Gerald Steven, additional, Pant, Shubham, additional, Cohen, Ezra E.W., additional, Wilky, Breelyn A., additional, Thompson, Benjamin, additional, Clynes, Raphael, additional, Li, Lingling, additional, McGovern, Patricia, additional, and Liebowitz, David Neal, additional

Published
2022
Full Text
View/download PDF

37. Phase I/II first-in-human CAR T–targeting MUC1 transmembrane cleavage product (MUC1*) in patients with metastatic breast cancer.

Author

Bamdad, Cynthia Carol, primary, Yuan, Yuan, additional, Specht, Jennifer M., additional, Stewart, Andrew K., additional, Smagghe, Benoit J., additional, Lin, Stephen Chi-Min, additional, Carter, Mark G., additional, Synold, Timothy W., additional, Frankel, Paul Henry, additional, Parekh, Vishwas, additional, Walkley, Danica M., additional, Budde, L Elizabeth, additional, Liu-Michael, Qing, additional, Nash, Jac-Leen, additional, Nash, Michael J., additional, Reale, Laura M., additional, Yi, Kevin Y., additional, Kim, Teresa, additional, Hamilton, Stanley R., additional, and Forman, Stephen J., additional

Published
2022
Full Text
View/download PDF

40. Abstract PD13-02: Phase Ib expansion study of gedatolisib in combination with palbociclib and endocrine therapy in women with ER+ metastatic breast cancer

Author

Layman, Rachel, primary, Wesolowski, Robert, additional, Han, Hyo, additional, Specht, Jennifer M, additional, Stringer-Reasor, Erica M, additional, Dees, E. Claire, additional, Kabos, Peter, additional, Mayer, Ingrid A, additional, Vaishampayan, Ulka, additional, Lu, Janice, additional, Gogineni, Keerthi, additional, Bardia, Aditya, additional, Schott, Anne F, additional, Abu-Khalaf, Maysa, additional, Howkins, Doug, additional, Sullivan, Brian, additional, Gorbatchevsky, Igor, additional, and Rugo, Hope, additional

Published
2022
Full Text
View/download PDF

42. First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors

Author

Do, Khanh T., primary, Chow, Laura Quan Man, additional, Reckamp, Karen, additional, Sanborn, Rachel E., additional, Burris, Howard, additional, Robert, Francisco, additional, Camidge, D. Ross, additional, Steuer, Conor E., additional, Strickler, John H., additional, Weise, Amy, additional, Specht, Jennifer M., additional, Gutierrez, Martin, additional, Haughney, Peter, additional, Hengel, Shawna, additional, Derleth, Christina Louise, additional, and Yap, Timothy A., additional

Published
2021
Full Text
View/download PDF

45. Additional file 1 of 18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study

Author

Romine, Perrin E., Peterson, Lanell M., Kurland, Brenda F., Byrd, Darrin W., Novakova-Jiresova, Alena, Muzi, Mark, Specht, Jennifer M., Doot, Robert K., Link, Jeanne M., Krohn, Kenneth A., Kinahan, Paul E., Mankoff, David A., and Linden, Hannah M.

Abstract

Additional file 1. Supplemental Material.

Published
2021
Full Text
View/download PDF

47. Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+ breast cancer (TBCRC 050).

Author

Stringer-Reasor, Erica Michelle, primary, Li, Yufeng, additional, Witherspoon, Felicia, additional, Specht, Jennifer M., additional, Anampa Mesias, Jesus Del Santo, additional, Nanda, Rita, additional, Dees, Elizabeth Claire, additional, Wolff, Antonio C., additional, Krop, Ian E., additional, Lin, Nancy U, additional, Rimawi, Mothaffar F., additional, and Yang, Eddy Shih-Hsin, additional

Published
2021
Full Text
View/download PDF

50. Abstract OT-03-03: SGNLVA-001: A phase 1 open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer

Author

Beckwith, Heather C, primary, Medgyesy, Diana C, additional, Abraham, Jame, additional, Nanda, Rita, additional, Tkaczuk, Katherine HR, additional, Krop, Ian E, additional, Pusztai, Lajos, additional, Modi, Shanu, additional, Mita, Monica M, additional, Specht, Jennifer M, additional, Hurvitz, Sara A, additional, Han, Hyo S, additional, Kalinsky, Kevin, additional, Wilks, Sharon, additional, O’Shaughnessy, Joyce, additional, Hart, Lowell L, additional, Rugo, Hope S, additional, Mitri, Zahi I, additional, Garfin, Phillip M, additional, and Burris, Howard A, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results